Kairos Pharma, LTD. Logo

Kairos Pharma, LTD.

Develops novel oncology therapies to reverse drug resistance and immune suppression.

KAPA | US

Overview

Corporate Details

ISIN(s):
US48301N1046
LEI:
Country:
United States of America
Address:
2355 WESTWOOD BLVD. #139, 90064 LOS ANGELES
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kairos Pharma, LTD. is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics for cancer patients. The company focuses on addressing two critical hurdles in oncology: overcoming resistance to cancer drugs and reversing cancer-induced immune suppression. Its lead candidate, ENV105, is an antibody designed to reverse drug resistance by targeting the CD105 protein; it is currently in Phase 2 trials for prostate cancer and Phase 1 for lung cancer. Kairos Pharma's immunotherapy pipeline includes KROS101, a small molecule to enhance T cell response, and KROS201, a T cell therapy targeting cancer stem cells in glioblastoma. The company's innovative approach aims to restore the efficacy of standard treatments and reactivate the patient's immune system to fight cancer.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kairos Pharma, LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kairos Pharma, LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Kairos Pharma, LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

A pharmaceutical specialist in drugs for renal, skin, and allergic diseases.
Japan
4551
Tourmaline Bio, Inc. Logo
Develops an anti-IL-6 antibody for cardiovascular, inflammatory, and immune diseases.
United States of America
TRML
TOWA PHARMACEUTICAL CO.,LTD. Logo
Manufactures and markets high-quality, accessible generic drugs for various therapeutic areas.
Japan
4553
Transcode Therapeutics, Inc. Logo
Develops targeted RNA therapies for metastatic cancer using a proprietary nanoparticle delivery platform.
United States of America
RNAZ
Travere Therapeutics, Inc. Logo
Develops therapies for rare kidney and metabolic diseases, with an FDA-approved treatment for IgA nephropathy.
United States of America
TVTX
Traws Pharma, Inc. Logo
Develops oral small-molecule therapies for respiratory viral diseases and cancer.
United States of America
TRAW
TScan Therapeutics, Inc. Logo
Developing TCR-engineered T-cell therapies for solid and hematologic cancers.
United States of America
TCRX
TSUMURA & CO. Logo
A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.
Japan
4540
TuHURA Biosciences, Inc./NV Logo
Phase 3 immuno-oncology firm developing therapeutics to overcome cancer therapy resistance.
United States of America
HURA
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish producer of pharmaceuticals, specializing in IV solutions and vaccines for hospitals.
Türkiye
TRILC

Talk to a Data Expert

Have a question? We'll get back to you promptly.